The Patent Cliff: $250bn at Stake and the Bidding War Behind the Curtain

On 1 January 2026, Medicare’s negotiated price for Bristol Myers Squibb and Pfizer’s anticoagulant Eliquis fell to $231 a month, down from a $521 list price, a 56% haircut imposed by federal statute on a drug that booked $13.2bn in global sales in 2024. Eleven months later, on 30 November 2026, Eliquis loses its core US composition patent and the apixaban generics enter at prices likely 85% below brand within twelve months. The pincer movement, Inflation Reduction Act on one flank and patent cliff on the other, is the defining strategic problem facing global pharma between now and 2030. Roughly $250bn of branded revenue is scheduled to leak to generics and biosimilars over the period, the largest forced asset reallocation in the industry’s history, and the M&A and pipeline bidding has already entered fever pitch.

The Scale of the Exposure. Keytruda is the single largest line item on the cliff. Merck’s PD-1 inhibitor generated $29.5bn in 2024 revenue, around 56% of the entire company, with consensus pointing to roughly $32.7bn by 2026 before its core US composition patent expires in 2028. Eliquis ($13.2bn, 2026 generics) and J&J’s Stelara ($10.9bn in 2023, already imploding) sit in the same tier. Opdivo, Xarelto, Eylea and a long tail of secondary blockbusters take the gross 2025-2030 exposure past $250bn on the most cited industry estimates and closer to $300bn on the wider tally. Stelara is the live demonstration of what happens when the cliff arrives. After its September 2023 US patent expiry, eight ustekinumab biosimilars launched at discounts of 46% to 90%, major pharmacy benefit managers stripped Stelara from formularies, sales fell 33.7% year-on-year in Q1 2025 and 42.7% in Q2, and J&J’s own consensus now models the franchise dropping from nearly $11bn in 2023 to around $2.7bn by 2027. Layered on top, the IRA-negotiated Stelara price took effect on 1 January 2026 at $4,695, down from $13,836. There is no soft landing scenario.

The Bidding War. The strategic response has been to buy what cannot be developed in time. Pfizer’s $43bn acquisition of Seagen in December 2023, the largest biopharma deal since 2019, was an explicit hedge against the loss of Ibrance, Xeljanz and a string of smaller assets, paid for in antibody-drug conjugate firepower. Merck’s $22bn collaboration with Daiichi Sankyo on three DXd-platform ADCs, signed in October 2023 with a $4bn upfront and $16.5bn in milestones, is the same trade, planted directly under the Keytruda cliff. Bristol Myers Squibb spent $14bn on Karuna Therapeutics in December 2023 for the schizophrenia asset KarXT, a deliberate move outside its cardiovascular and oncology base ahead of the Eliquis cliff. Vertex paid $4.9bn for Alpine Immune Sciences in April 2024 to acquire the IgA nephropathy candidate povetacicept, its largest deal ever. 2025 deepened the pattern: Johnson & Johnson bought Intra-Cellular Therapies for $14.6bn, Merck took out Verona Pharma for $10bn for the COPD drug Ohtuvayre, Sanofi acquired Blueprint Medicines for $9.5bn, Genmab paid $8bn for Merus, and Novo Nordisk took Akero Therapeutics for $5.2bn. In 2024 and 2025, oncology accounted for more billion-dollar deals than any other therapeutic area. The unifying logic is brutally simple. Big Pharma is buying replacement IP at any price the market clears.

The GLP-1 Offset. The one franchise capable of offsetting the cliff at industry scale is metabolic. Eli Lilly’s Mounjaro generated approximately $23bn in 2025, Zepbound contributed $13.5bn, and the combined GLP-1 franchise overtook Keytruda mid-year to become the world’s best-selling drug. Lilly crossed a $1 trillion market capitalisation in November 2025, the first healthcare company in history to do so, and guides 2026 revenue to $82bn-$85bn. Independent forecasts put the global GLP-1 market at $100bn in annual sales by 2030. Yet the offset is concentrated rather than distributed. Lilly and Novo Nordisk capture the upside; Pfizer, Bristol Myers Squibb, Merck and Sanofi do not. And the metabolic window is closing faster than commonly understood. Semaglutide’s core compound patent expired in India on 20 March 2026, triggering generic launches within twenty-four hours, with at least forty Indian players and more than fifty brands queued, and Pharmarack forecasting price falls of 30-50% initially and 70-75% over time. The same patent lapsed in 2026 across China, Brazil and South Africa, jurisdictions accounting for roughly 48% of the global obesity burden. Dr Reddy’s intends to launch semaglutide across 87 countries through 2027. The US compound patent runs to 2032, but the global pricing reference point is already breaking.

Supply Chain as Strategic Variable. The cliff also exposes the geography of generic production, and Western policymakers are paying attention. India shipped roughly $9.7bn of pharmaceutical product to the United States in FY 2024-25, supplies more than 40% of US generics by volume, and accounts for around 20% of global generic exports across roughly 60,000 brand names. China remains India’s own dominant API supplier; only about 15% of Indian API consumption is domestically produced by volume, leaving a single chokepoint upstream of the entire Western generics market. As the cliff converts $250bn of branded revenue into generic equivalents, dependence on this corridor mechanically deepens. The Trump administration’s September 2025 announcement of a 100% tariff on patented pharmaceutical imports, paired with an explicit exemption for generic drugs, signals that Washington has already decided which leg of the supply chain it can afford to disturb. Europe is further behind, having reduced API self-sufficiency below 30% for most therapeutic categories over the last two decades, and the Critical Medicines Act tabled in March 2025 will not meaningfully shift production for years. Strategic medicine supply is now a sovereignty question, not a procurement one.

The IRA Compounding Effect. Patent cliffs are cyclical; the Inflation Reduction Act is structural. The first round of CMS negotiation, effective 1 January 2026, applied to ten drugs accounting for around $50.5bn in annual Medicare Part D spending, with discounts of 38% to 79% off list. Three drugs alone, Eliquis, Stelara and the diabetes franchise Jardiance, account for 51.4% of the projected $6bn in Medicare savings in 2026. A further fifteen drugs are scheduled for negotiation in cycle two, fifteen more in cycle three including selected Part B drugs from 2028, and twenty per year thereafter. The arithmetic for Big Pharma is that the moment a drug crosses the threshold for negotiation eligibility, typically nine to thirteen years post-launch depending on small molecule versus biologic status, it begins losing revenue before its formal patent cliff arrives. This collapses the effective monetisation window and shifts pipeline economics towards biologics, cell and gene therapy, and indications with shorter accepted approval timelines.

The Shape of the Survivor. The industry that emerges in 2030 will look materially different from today’s. Three franchises stand out as durable revenue bases: oncology built on ADC and bispecific platforms, GLP-1 and successor metabolic agents, and cell and gene therapy where manufacturing complexity itself acts as a moat. Around these clusters sits a far larger universe of generic and biosimilar volume, increasingly contested by Indian, Chinese and Korean players, with Western strategic concern about that production base rising in parallel. The diversified Big Pharma without genuine pipeline depth, the cohort that built itself around one or two cardiovascular or immunology blockbusters and has bought time rather than position, will be acquirers in name and consolidation targets in fact. Pfizer, Bristol Myers Squibb and Bayer sit closest to that line on current trajectory; Merck and J&J are spending hard to avoid it; Roche and AstraZeneca are arguably ahead of the curve through earlier oncology repositioning.

The Verdict. The 2025-2030 patent cliff is not a downturn to be ridden out, it is a forced reallocation of capital and IP across the largest single therapeutic-class transition since the arrival of monoclonal antibodies. Winners are already legible: obesity and metabolic at Lilly and Novo Nordisk, ADC-equipped oncology houses, and early-stage biotech holding the platforms that Big Pharma must now buy. Losers are the diversified incumbents whose 2030 P&L still depends on assets currently subsidising their M&A budgets. The bidding war behind the curtain is not a strategy, it is the new operating regime, and it will continue at scale for as long as $250bn of revenue is in motion.

Read our full Report Disclaimer.